These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 31153807)

  • 1. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7).
    Ljungman P; de la Camara R; Robin C; Crocchiolo R; Einsele H; Hill JA; Hubacek P; Navarro D; Cordonnier C; Ward KN;
    Lancet Infect Dis; 2019 Aug; 19(8):e260-e272. PubMed ID: 31153807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Efficacy and Safety of Different Antiviral Agents for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis.
    Gagelmann N; Ljungman P; Styczynski J; Kröger N
    Biol Blood Marrow Transplant; 2018 Oct; 24(10):2101-2109. PubMed ID: 29777868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral prophylaxis in haematological patients: systematic review and meta-analysis.
    Yahav D; Gafter-Gvili A; Muchtar E; Skalsky K; Kariv G; Yeshurun M; Leibovici L; Paul M
    Eur J Cancer; 2009 Dec; 45(18):3131-48. PubMed ID: 19796930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia.
    Bergeron A; Mikulska M; De Greef J; Bondeelle L; Franquet T; Herrmann JL; Lange C; Spriet I; Akova M; Donnelly JP; Maertens J; Maschmeyer G; Rovira M; Goletti D; de la Camara R;
    Lancet Infect Dis; 2022 Dec; 22(12):e359-e369. PubMed ID: 35636446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5).
    Mallet V; van Bömmel F; Doerig C; Pischke S; Hermine O; Locasciulli A; Cordonnier C; Berg T; Moradpour D; Wedemeyer H; Ljungman P;
    Lancet Infect Dis; 2016 May; 16(5):606-617. PubMed ID: 27599653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic strategies for cytomegalovirus infection in haematopoietic transplant recipients: a focused update.
    Sellar RS; Peggs KS
    Expert Opin Biol Ther; 2014 Aug; 14(8):1121-6. PubMed ID: 24762099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maribavir, brincidofovir and letermovir: Efficacy and safety of new antiviral drugs for treating cytomegalovirus infections.
    Frange P; Leruez-Ville M
    Med Mal Infect; 2018 Dec; 48(8):495-502. PubMed ID: 29650261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation.
    Razonable RR
    Curr Opin Infect Dis; 2018 Aug; 31(4):286-291. PubMed ID: 29746444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prevention and treatment of cytomegalovirus infection in haematopoietic stem cell transplantation.
    Tuthill M; Chen F; Paston S; De La Peña H; Rusakiewicz S; Madrigal A
    Cancer Immunol Immunother; 2009 Sep; 58(9):1481-8. PubMed ID: 19466407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Letermovir and maribavir for pan-resistant cytomegalovirus infection in a patient with haematologic malignancy: Consideration for combination therapy.
    Dickter JK; Ross JA; Zain JM; Tegtmeier BR; Lee BV; Dadwal SS
    J Clin Pharm Ther; 2022 May; 47(5):699-702. PubMed ID: 35023177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diagnosis, treatment, and prophylaxis for cytomegalovirus disease following allogeneic stem cell transplantation].
    Gondo H
    Rinsho Ketsueki; 2003 Dec; 44(12):1154-60. PubMed ID: 14978931
    [No Abstract]   [Full Text] [Related]  

  • 12. Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9).
    Cesaro S; Mikulska M; Hirsch HH; Styczynski J; Meylan S; Cordonnier C; Navarro D; von Lilienfeld-Toal M; Mehra V; Marchesi F; Besson C; Masculano RC; Beutel G; Einsele H; Maertens J; de la Camara R; ; Ljungman P; Pagano L
    Leukemia; 2023 Sep; 37(9):1933-1938. PubMed ID: 37460673
    [No Abstract]   [Full Text] [Related]  

  • 13. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients.
    Avery RK; Marty FM; Strasfeld L; Lee I; Arrieta A; Chou S; Tatarowicz W; Villano S
    Transpl Infect Dis; 2010 Dec; 12(6):489-96. PubMed ID: 20682012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cytomegalovirus infections following allogeneic hematopoietic stem cell transplantation: prophylaxis and treatment].
    Katayama Y; Iwato K
    Rinsho Ketsueki; 2019; 60(6):635-645. PubMed ID: 31281156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Foscarnet in the management of cytomegalovirus infections in hematopoietic stem cell transplant patients.
    Bacigalupo A; Boyd A; Slipper J; Curtis J; Clissold S
    Expert Rev Anti Infect Ther; 2012 Nov; 10(11):1249-64. PubMed ID: 23167560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN.
    Engelhard D; Mohty B; de la Camara R; Cordonnier C; Ljungman P
    Transpl Infect Dis; 2013 Jun; 15(3):219-32. PubMed ID: 23363310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients.
    Ruiz-Camps I; Len O; de la Cámara R; Gurguí M; Martino R; Jarque I; Barrenetxea C; Díaz de Heredia C; Batlle M; Rovira M; de la Torre J; Torres A; Aguilar M; Espigado I; Martín-Dávila P; Bou G; Borrell N; Aguado JM; Pahissa A;
    Antivir Ther; 2011; 16(7):951-7. PubMed ID: 22024510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management and prevention of cytomegalovirus infection in paediatric hematopoietic stem cell transplant (HSCT) recipients: A binational survey.
    Al Yazidi LS; Mitchell R; Palasanthiran P; O'Brien TA; McMullan B
    Pediatr Transplant; 2019 Aug; 23(5):e13458. PubMed ID: 31081265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Management of cytomegalovirus infection after hematopoietic stem cell transplantation].
    Mori T
    Rinsho Ketsueki; 2019; 60(9):1337-1340. PubMed ID: 31597861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial.
    Marty FM; Ljungman P; Papanicolaou GA; Winston DJ; Chemaly RF; Strasfeld L; Young JA; Rodriguez T; Maertens J; Schmitt M; Einsele H; Ferrant A; Lipton JH; Villano SA; Chen H; Boeckh M;
    Lancet Infect Dis; 2011 Apr; 11(4):284-92. PubMed ID: 21414843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.